Florida Translational Research Program (FTRP)

Florida Translational Research Program (FTRP)

Funding discovery of new drugs to fight disease and reduce future healthcare costs.

FTRP is Collaborative

FTRP is Collaborative

100% Florida universities with biomedical programs participate in FTRP to discover potential new medicines.

FTRP is Competitive

FTRP is Competitive

All research is approved by third-party peer-review process using the NIH review model.

FTRP is Peer Reviewed

FTRP is Peer Reviewed

External peer review experts from academia and pharma/biotechnology industries select the most promising projects for acceptance.

The FTRP is novel and great. It will greatly increase the chance that Florida will have spinout biotech companies.

- Claes Wahlestedt, M.D., Ph.D.

University of Miami

We are pleased to announce that the FTRP was funded by the Florida legislature for FY 2016-2017.

SBP thanks Governor Scott, the Senate and House of Representatives for supporting biomedical research and recognizing the power of the FTRP to translate discoveries statewide into breakthrough medicines.

The next open solicitation for research proposals will be Fall, 2016. Proposals currently in the pipeline will be reviewed and new project announcements will be made July, 2016.

Program Participants

Florida Translational Research Program

The Florida Translational Research Program (FTRP) funds the discovery of new drugs to fight disease and reduce future healthcare costs. Discoveries emerging from research labs statewide are enhanced at SBP’s drug discovery center to create a pipeline of potential new medicines to fight cancer, Alzheimer’s disease, diabetes and to generate IP revenue. This university affiliated program has 100% participation by Florida universities with biomedical programs.


  • Translates breakthrough discoveries from universities & nonprofit institutes into first-in-class therapeutics for patients.
  • Leverages the state’s investment in SBP’s drug discovery platform – the most advanced in the state & nonprofit world.
  • Accelerates the growth of Florida’s life sciences industry and advances discoveries to a stage that will be attractive for commercial investment.
  • Is competitive – proposals are evaluated through a 3rd party peer-review process using the NIH review model.

Success to-date

  • Five pending patents
  • Nearly $5 million in out-of-state research funding
  • Commitments from venture capital firms to commercialize discoveries
  • Completed 64 projects in cancer, neurological, diabetes, and infectious disease research

Read more about our current status

Case Histories


University of South Florida

Dr. Kevin Nash has identified a protein that can reduce inflammation in diseased brains and rescue neurons. The USF/SBP team sought to identify molecules that would mimic the anti-inflammatory protein. Equipped with strong data, Dr. Nash has applied for an Alzheimer’s Drug Discovery Foundation grant. With renewed FTRP funding, Dr. Nash would advance his research, apply for NIH funding, and begin clinical trials.


Mayo Clinic Jacksonville

Dr. Pamela McLean is searching for breakthrough Parkinson’s disease therapies. Her FTRP collaboration provided access to SBP’s 900,000 compound library and industry-trained drug discovery experts. Initial results led to a Michael J. Fox Foundation award—the largest MJFF grant ever awarded—demonstrating the ability of FTRP to enhance Florida research and attract out-of-state funding.


Moffitt Cancer Center

Drs. Said Sebti and Nicholas Lawrence are leading the charge to identify potent small molecules that will suppress tumor growth. With FTRP support, the Moffitt/SBP team seeks to identify chemicals that will kill cancer cells and then advance the compounds to the clinic, where they hope to broaden the spectrum of tumors that can be successfully treated.


Florida International University

Dr. Yuk-Ching Tse-Dinh seeks to discover new antibiotics to combat multidrug-resistant infections. Working with Dr. Tse-Dinh, SBP drug discovery scientists searched for new chemicals that might kill antibiotic-resistant bacteria. The need is great since all antibiotics in use today were discovered more than 30 years ago. The FTRP funding put research back on course to address the worldwide crisis.


University of Florida

Dr. Kirk Conrad studies relaxin, one of the body’s molecules that control blood pressure. His FTRP funded collaboration with SBP led the team to identify potential drug like molecules that mimic the effects of relaxin in test tubes, which in time may be the next best medicine for treating heart failure. This project has attracted the interest of a major pharmaceutical company.

Sign In Skip Navigation Links Skip navigation links
About the Prebys Center
Outreach & Funding Opportunities